A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Chen, Yuan , Ph.D. Bookmark and Share

Yuan Chen, Ph.D. Research

 
Ubiquitin-like Modifications
Our current research interest is in protein modifications by a family of small proteins known as ubiquitin and its homologues. These modifications control life spans, trafficking, assembly and enzymatic activities of cellular proteins, and are important in nearly every aspect of biological functions. We employ a combination of structural, biochemical, molecular and cellular biological methods to understand these processes in cellular regulation and disease pathogenesis. Specific areas of interest are outlined below.

The Role of SUMOylation in Oncogenesis
Post-translational modifications by the small ubiquitin-like modifiers (SUMO) are important in oncogenesis and cellular response to DNA damage. Recent findings indicate that the key oncogenic pathways driven by Myc and KRas are dependent on, or addicted to, SUMOylation. For example, knocking down of the gene encoding the catalytic subunit of the SUMO activating enzyme (SAE), SAE2, has the strongest synthetic lethal interaction with Myc hyperactivation. We are investigating the molecular mechanisms underlying the synthetic lethality of SUMOylation with Myc hyperactivation and KRas mutations. In addition, we are investigating the structure-activity relationship of how the inhibitors interact with the SAE and inhibit its enzymatic activity, and use this information to guide further improvement of the inhibitors. These studies could potentially improve treatment of many cancers, as overexpression of Myc is estimated to contribute to 70 percent of all human cancers, and KRas is also frequently mutated in human cancers.

SUMO Modifications and HIV Replication
SUMO-specific proteases (SENP) regulate post-translational modifications by SUMO through catalyzing the maturation of SUMO precursors and the removal of SUMO from modified proteins. Small molecule inhibitors of SENPs that function in cells would be valuable tools for elucidating the functions of SENPs. We have recently identified a family of small molecule inhibitors of SENPs that inhibit de-SUMOylation activities in cells. Coincidently, these small molecules had been shown to confer anti-HIV activities in a National Cancer Institute antiviral screen, although the cellular targets and the mechanism of inhibition of HIV were unknown. We are investigating the molecular mechanism of how SUMOylation is involved in HIV life cycle. In addition, we are conducting the structure-activity relationship studies of how these inhibitors interact with the SENPs and inhibit their enzymatic activity, and use this information to develop improved inhibitors. Furthermore, we are interested in exploiting this pathway to develop a potential strategy for a cure of HIV by allowing the immune system to target HIV infected cells without producing infectious virus.

NMR-based Metabolomics
Metabolic activity is a reflection of cellular functions. Our laboratory utilizes nuclear magnetic resonance (NMR) spectroscopy as tools for metabolomic studies, that is, global analysis of metabolic activities. Our goal is to provide information on cellular pathways to understand metabolic dysfunctions of cancer cells.

Application of NMR Methods in Drug Discovery
We are collaborating with several other laboratories with expertise in synthetic chemistry, molecular biology and medical oncology to develop new therapeutics for cancer. State-of-the-art NMR methods are employed to provide information on protein-ligand interactions at an atomic resolution; information that is critical for the rational design of new therapeutics.
 
Representative Publications:
 
Gold nanoparticles as a platform for creating a multivalent poly-SUMO chain inhibitor that also augments ionizing radiation
YJ Li, AL Perkins, Y Su, Y Ma, L Colson, DA Horne, Y Chen
Proceedings of the National Academy of Sciences 109 (11), 4092-4097, 2012
 
The intrinsic affinity between E2 and the Cys domain of E1 in ubiquitin-like modifications
J Wang, W Hu, S Cai, B Lee, J Song, Y Chen
Molecular cell 27 (2), 228-237, 2007
 
Identification of a SUMO-binding motif that recognizes SUMO-modified proteins
Jing Song, Linda K Durrin, Thomas A Wilkinson, Theodore G Krontiris, Yuan Chen
Proceedings of the National Academy of Sciences of the United States of America, 101 (40), 14373-14378, 2004
 
More publications can be found at:
http://scholar.google.com/citations?user=zgAR9fsAAAAJ&hl=en
 

Yuan Chen, Ph.D. Facilities

NMR Facility
 
Computers and Software
  • Six Linex workstations
  • Two multi-processor servers
  • Software include: InsightII, FELIX, NMRVIEW, NMRDRAW, PIPE, MOLMOL, DYANA, CNS, ARIA, HADDOCK and AMBER.
 
Other Shared Equipment
  • Isothermal titration calorimeter
  • Jasco CD instrument
  • Automated Applied Biosystems (AB) Procise Protein Sequencing System for N-terminal Edman degradation
  • A Perkin Applied Biosystems Procise C-terminal sequencer and a Hewlett Packard C-terminal sequencer
  • Dionex AAA Direct amino acid analyzer
  • HPLC systems suitable for narrow-bore and microcapillary chromatography and equipped for detection of peptides at 214 nm as well as variable wavelength fluorescence detection
  • Pharmacia FPLC for protein purification
  • Perkin-Elmer FTIR
  • Hitachi UV/VIS Spectrophotometer
  • Pharmacia BIAcoreTM System
  • PerSeptive Biosystems BioCAD/SPRINT
  • Bio-Rad scanning Densitometer
  • Three Thermo Finnigan LCQ family ion traps (two Classic and one Deca) equipped with electrospray/LC sources.
  • An Applied Biosystems Mariner electrospray (ES) Orthogonal TOF spectrometer
  • Applied Biosystems Voyager DE STR MALDI-TOF spectrometer
  • Scintillation and gamma counters
  • Wallac Micro Beta counter
  • Tomtec 96-well plate harvester
 

Lab Members

 
Current Lab Members

Shannon Maldonado
Senior Administrative Analyst
 
Ramir Vega
Research Associate
 
Grace Aldana-Masangkay, Ph.D.
Research Fellow
 
Aileen Alontaga, Ph.D.
Research Fellow
 
Nigus D Ambaye, Ph.D.
Research Fellow

Chih-Hong Chen, Ph.D.
Research Fellow

Li Du, Ph.D.
Research Fellow
 
Yi-Jia Li, Ph.D.
Staff Scientist
 
Alumni

Postdoctoral fellows
Yate-Ching Yuan, Ph.D.
Director of the Bioinformatic Core Facility at Beckman Research Institute of City of Hope

Maria Victoria Botuyan, Ph.D.
Staff scientist at Mayo Clinic, MN, USA

Jerry Hu, Ph.D.
Manager, Materials Research Laboratory Spectroscopy Facility, UC Santa Barbara

Donghai Lin, Ph.D.
Professor at Shanghai Institute of Materia Medica, Chinese Academy of Sciences. 

Suhkmann Kim, Ph.D.
Associate Professor at Pusan National University, Korea. 

Sheng Cai, Ph.D.
Director of the NMR laboratory at Marquette University, Wisconsin, USA

Lingyang Zhu, Ph.D.
Senior Scientist, Array BioPharma Inc. Boulder, CO

Thomas Wilkinson, Ph.D.
Staff Scientist, UCLA

Xuanjun Ai, Ph.D.
Postdoctoral fellow with Dr. Charalampos Kalodimos at Rutgers University
 
Ikenna Madu, Ph.D.
Scientist Kineta, Inc, Seattle, WA
 
Yang Su, Ph.D.
Beijing, China
 
Jianghai Wang, Ph.D.
Senior Scientist, BostonBiochem, MA, USA
 
Yifei Li, Ph.D.
NCI at Frederick, Frederick, MD
 
Graduate students
Ziming Zhang, Ph.D. (2004)
Director of the Nuclear Magnetic Resonance Core, University of South Florida

Jing Song, Ph.D. (2006)
Jing spent two years as a postdoctoral fellow with Professor Timothy Springer at Harvard Medical School, and now is group leader at BioDuro.

Khue Truong, Ph.D. (2012)
Post doctoral fellow at UCLA.

Research technicians
Qin Liu, M.S., Biomolecular NMR Facility manager, Department of Biochemistry, University of Western Ontario, Canada

Candace Seu, Ph.D. student, UC San Diego

Lisa Fukui, M.D/Ph.D. student, University of Illinois at Urbane Champion

Brian Lee, medical student, SUNY Stony Brook

Larry Tong, medical student, University of Nebraska

Steven Wong, medical student, UCLA
 

Yuan Chen, Ph.D. NvMap Agreement Download

Academic (nonprofit) License Agreement
 
Please send two signed originals of the license agreement to:
 
City of Hope
1500 East Duarte Road
Duarte, California 91010
Attn.:  Director, Office of Technology Licensing
Fax: 626-301-8175
 
With a copy to:
 
Dr. Yuan Chen
Department of Molecular Medicine
City of Hope
1500 East Duarte Road
Duarte, California 91010
Fax: 626-301-8186
 
Industry License Agreement
 
For more information please contact:
 
Matthew Grunseth, M.B.S.
Technology Licensing Manager
mgrunseth@coh.org
 

Chen, Yuan , Ph.D.

Yuan Chen, Ph.D. Research

 
Ubiquitin-like Modifications
Our current research interest is in protein modifications by a family of small proteins known as ubiquitin and its homologues. These modifications control life spans, trafficking, assembly and enzymatic activities of cellular proteins, and are important in nearly every aspect of biological functions. We employ a combination of structural, biochemical, molecular and cellular biological methods to understand these processes in cellular regulation and disease pathogenesis. Specific areas of interest are outlined below.

The Role of SUMOylation in Oncogenesis
Post-translational modifications by the small ubiquitin-like modifiers (SUMO) are important in oncogenesis and cellular response to DNA damage. Recent findings indicate that the key oncogenic pathways driven by Myc and KRas are dependent on, or addicted to, SUMOylation. For example, knocking down of the gene encoding the catalytic subunit of the SUMO activating enzyme (SAE), SAE2, has the strongest synthetic lethal interaction with Myc hyperactivation. We are investigating the molecular mechanisms underlying the synthetic lethality of SUMOylation with Myc hyperactivation and KRas mutations. In addition, we are investigating the structure-activity relationship of how the inhibitors interact with the SAE and inhibit its enzymatic activity, and use this information to guide further improvement of the inhibitors. These studies could potentially improve treatment of many cancers, as overexpression of Myc is estimated to contribute to 70 percent of all human cancers, and KRas is also frequently mutated in human cancers.

SUMO Modifications and HIV Replication
SUMO-specific proteases (SENP) regulate post-translational modifications by SUMO through catalyzing the maturation of SUMO precursors and the removal of SUMO from modified proteins. Small molecule inhibitors of SENPs that function in cells would be valuable tools for elucidating the functions of SENPs. We have recently identified a family of small molecule inhibitors of SENPs that inhibit de-SUMOylation activities in cells. Coincidently, these small molecules had been shown to confer anti-HIV activities in a National Cancer Institute antiviral screen, although the cellular targets and the mechanism of inhibition of HIV were unknown. We are investigating the molecular mechanism of how SUMOylation is involved in HIV life cycle. In addition, we are conducting the structure-activity relationship studies of how these inhibitors interact with the SENPs and inhibit their enzymatic activity, and use this information to develop improved inhibitors. Furthermore, we are interested in exploiting this pathway to develop a potential strategy for a cure of HIV by allowing the immune system to target HIV infected cells without producing infectious virus.

NMR-based Metabolomics
Metabolic activity is a reflection of cellular functions. Our laboratory utilizes nuclear magnetic resonance (NMR) spectroscopy as tools for metabolomic studies, that is, global analysis of metabolic activities. Our goal is to provide information on cellular pathways to understand metabolic dysfunctions of cancer cells.

Application of NMR Methods in Drug Discovery
We are collaborating with several other laboratories with expertise in synthetic chemistry, molecular biology and medical oncology to develop new therapeutics for cancer. State-of-the-art NMR methods are employed to provide information on protein-ligand interactions at an atomic resolution; information that is critical for the rational design of new therapeutics.
 
Representative Publications:
 
Gold nanoparticles as a platform for creating a multivalent poly-SUMO chain inhibitor that also augments ionizing radiation
YJ Li, AL Perkins, Y Su, Y Ma, L Colson, DA Horne, Y Chen
Proceedings of the National Academy of Sciences 109 (11), 4092-4097, 2012
 
The intrinsic affinity between E2 and the Cys domain of E1 in ubiquitin-like modifications
J Wang, W Hu, S Cai, B Lee, J Song, Y Chen
Molecular cell 27 (2), 228-237, 2007
 
Identification of a SUMO-binding motif that recognizes SUMO-modified proteins
Jing Song, Linda K Durrin, Thomas A Wilkinson, Theodore G Krontiris, Yuan Chen
Proceedings of the National Academy of Sciences of the United States of America, 101 (40), 14373-14378, 2004
 
More publications can be found at:
http://scholar.google.com/citations?user=zgAR9fsAAAAJ&hl=en
 

Facilities

Yuan Chen, Ph.D. Facilities

NMR Facility
 
Computers and Software
  • Six Linex workstations
  • Two multi-processor servers
  • Software include: InsightII, FELIX, NMRVIEW, NMRDRAW, PIPE, MOLMOL, DYANA, CNS, ARIA, HADDOCK and AMBER.
 
Other Shared Equipment
  • Isothermal titration calorimeter
  • Jasco CD instrument
  • Automated Applied Biosystems (AB) Procise Protein Sequencing System for N-terminal Edman degradation
  • A Perkin Applied Biosystems Procise C-terminal sequencer and a Hewlett Packard C-terminal sequencer
  • Dionex AAA Direct amino acid analyzer
  • HPLC systems suitable for narrow-bore and microcapillary chromatography and equipped for detection of peptides at 214 nm as well as variable wavelength fluorescence detection
  • Pharmacia FPLC for protein purification
  • Perkin-Elmer FTIR
  • Hitachi UV/VIS Spectrophotometer
  • Pharmacia BIAcoreTM System
  • PerSeptive Biosystems BioCAD/SPRINT
  • Bio-Rad scanning Densitometer
  • Three Thermo Finnigan LCQ family ion traps (two Classic and one Deca) equipped with electrospray/LC sources.
  • An Applied Biosystems Mariner electrospray (ES) Orthogonal TOF spectrometer
  • Applied Biosystems Voyager DE STR MALDI-TOF spectrometer
  • Scintillation and gamma counters
  • Wallac Micro Beta counter
  • Tomtec 96-well plate harvester
 

Lab Members and Alumni

Lab Members

 
Current Lab Members

Shannon Maldonado
Senior Administrative Analyst
 
Ramir Vega
Research Associate
 
Grace Aldana-Masangkay, Ph.D.
Research Fellow
 
Aileen Alontaga, Ph.D.
Research Fellow
 
Nigus D Ambaye, Ph.D.
Research Fellow

Chih-Hong Chen, Ph.D.
Research Fellow

Li Du, Ph.D.
Research Fellow
 
Yi-Jia Li, Ph.D.
Staff Scientist
 
Alumni

Postdoctoral fellows
Yate-Ching Yuan, Ph.D.
Director of the Bioinformatic Core Facility at Beckman Research Institute of City of Hope

Maria Victoria Botuyan, Ph.D.
Staff scientist at Mayo Clinic, MN, USA

Jerry Hu, Ph.D.
Manager, Materials Research Laboratory Spectroscopy Facility, UC Santa Barbara

Donghai Lin, Ph.D.
Professor at Shanghai Institute of Materia Medica, Chinese Academy of Sciences. 

Suhkmann Kim, Ph.D.
Associate Professor at Pusan National University, Korea. 

Sheng Cai, Ph.D.
Director of the NMR laboratory at Marquette University, Wisconsin, USA

Lingyang Zhu, Ph.D.
Senior Scientist, Array BioPharma Inc. Boulder, CO

Thomas Wilkinson, Ph.D.
Staff Scientist, UCLA

Xuanjun Ai, Ph.D.
Postdoctoral fellow with Dr. Charalampos Kalodimos at Rutgers University
 
Ikenna Madu, Ph.D.
Scientist Kineta, Inc, Seattle, WA
 
Yang Su, Ph.D.
Beijing, China
 
Jianghai Wang, Ph.D.
Senior Scientist, BostonBiochem, MA, USA
 
Yifei Li, Ph.D.
NCI at Frederick, Frederick, MD
 
Graduate students
Ziming Zhang, Ph.D. (2004)
Director of the Nuclear Magnetic Resonance Core, University of South Florida

Jing Song, Ph.D. (2006)
Jing spent two years as a postdoctoral fellow with Professor Timothy Springer at Harvard Medical School, and now is group leader at BioDuro.

Khue Truong, Ph.D. (2012)
Post doctoral fellow at UCLA.

Research technicians
Qin Liu, M.S., Biomolecular NMR Facility manager, Department of Biochemistry, University of Western Ontario, Canada

Candace Seu, Ph.D. student, UC San Diego

Lisa Fukui, M.D/Ph.D. student, University of Illinois at Urbane Champion

Brian Lee, medical student, SUNY Stony Brook

Larry Tong, medical student, University of Nebraska

Steven Wong, medical student, UCLA
 

Agreement Download

Yuan Chen, Ph.D. NvMap Agreement Download

Academic (nonprofit) License Agreement
 
Please send two signed originals of the license agreement to:
 
City of Hope
1500 East Duarte Road
Duarte, California 91010
Attn.:  Director, Office of Technology Licensing
Fax: 626-301-8175
 
With a copy to:
 
Dr. Yuan Chen
Department of Molecular Medicine
City of Hope
1500 East Duarte Road
Duarte, California 91010
Fax: 626-301-8186
 
Industry License Agreement
 
For more information please contact:
 
Matthew Grunseth, M.B.S.
Technology Licensing Manager
mgrunseth@coh.org
 
Our Scientists

Our research laboratories are led by the best and brightest minds in scientific research.
 

Beckman Research Institute of City of Hope is internationally  recognized for its innovative biomedical research.
City of Hope is one of only 41 Comprehensive Cancer Centers in the country, the highest designation awarded by the National Cancer Institute to institutions that lead the way in cancer research, treatment, prevention and professional education.
Learn more about City of Hope's institutional distinctions, breakthrough innovations and collaborations.
Develop new therapies, diagnostics and preventions in the fight against cancer and other life-threatening diseases.
 
Support Our Research
By giving to City of Hope, you support breakthrough discoveries in laboratory research that translate into lifesaving treatments for patients with cancer and other serious diseases.
 
 
 
 
NEWS & UPDATES
  • Cancer research has yielded scientific breakthroughs that offer patients more options, more hope for survival and a higher quality of life than ever before. The 14.5 million cancer patients living in the United States are living proof that cancer research saves lives. Now, in addition to the clinic, hospital an...
  • Advances in cancer treatment, built on discoveries made in the laboratory then brought to the bedside, have phenomenally changed the reality of living with a cancer diagnosis. More than any other time in history, people diagnosed with cancer are more likely to survive and to enjoy a high quality of life. Howeve...
  • While health care reform has led to an increase in the number of people signing up for health insurance, many people remain uninsured or are not taking full advantage of the health benefits they now have. Still others are finding that, although their premiums are affordable, they aren’t able to see the do...
  • Kidney cancer rates and thyroid cancer rates in adults have continued to rise year after year. Now a new study has found that incidence rates for these cancers are also increasing in children — particularly in African-American children. The study, published online this month in Pediatrics, examined childhood ca...
  • Thyroid cancer has become one of the fastest-growing cancers in the United States for both men and women. The chance of being diagnosed with the cancer has nearly doubled since 1990. This year an estimated 63,000 people will be diagnosed with thyroid cancer in the United States and nearly 1,900 people will die ...
  • Older teenagers and young adults traditionally face worse outcomes than younger children when diagnosed with brain cancer and other central nervous system tumors. A first-of-its-kind study shows why. A team of researchers from the departments of Population Sciences and Pathology at City of Hope recently examine...
  • Cancer treatment can take a toll on the mouth, even if a patient’s cancer has nothing to do with the head or throat, leading to a dry mouth, or a very sore mouth, and making it difficult to swallow or eat. Here’s some advice from the National Cancer Institute (NCI)  on how to ease cancer-related dis...
  • Radiation oncology is one of the three main specialties involved in the successful treatment of cancer, along with surgical oncology and medical oncology. Experts in this field, known as radiation oncologists, advise patients as to whether radiation therapy will be useful for their cancer – and how it can best ...
  • There’s more to cancer care than simply helping patients survive. There’s more to cancer treatment than simple survival. Constant pain should not be part of conquering cancer,  insists Betty Ferrell, Ph.D., R.N., director of nursing research and education at City of Hope. She wants patients and caregivers...
  • Even its name is daunting. Systemic mastocytosis is a fatal disease of the blood with no known cure. But a new study suggests a bone marrow transplant may be the answer for some patients. While rare, systemic mastocytosis is resistant to treatment with drugs and, when aggressive, can be fatal within four years ...
  • Could what you eat affect the health of your chromosomes? The short answer is, “Yes.” Researchers led by Dustin Schones, Ph.D., assistant professor in the Department of Cancer Biology, and Rama Natarajan, Ph.D., director of the Division of Molecular Diabetes Research and the National Business Products Industry ...
  • September is Prostate Cancer Awareness Month. Here, Bertram Yuh, M.D., assistant clinical professor in the Division of Urology and Urologic Oncology at City of Hope, explains the importance of understanding the risk factors for the disease and ways to reduce those risks, as well as overall prostate health. “Wha...
  • ** Learn more about prostate health, plus prostate cancer research and treatment, at City of Hope. ** Learn more about getting a second opinion at City of Hope by visiting us online or by calling 800-826-HOPE (4673). City of Hope staff will explain what’s required for a consult at City of Hope and help yo...
  • Childhood cancer survival rates have increased dramatically over the past 40 years. More than 80 percent of children with cancer now survive five years or more, which is a tremendous feat. Despite the survival rate increase, cancer continues to be the No. 1 disease killer and second-leading cause of death in ch...
  • Although a stem cell transplant can be a lifesaving procedure for people diagnosed with a blood cancer or blood disorder, the standard transplant may not be appropriate for all patients. This is because the conditioning regimen (the intensive chemotherapy and/or radiation treatments preceding the transplant) is...